Highlights
The PARTHENOPE trial provides landmark evidence for the clinical superiority of individualized dual antiplatelet therapy (DAPT) strategies. The key findings include:
- Personalizing DAPT duration between 3 and 24 months based on validated risk scores significantly reduced the primary endpoint of Net Adverse Clinical Events (NACE) at 24 months compared to a fixed 12-month regimen.
- The benefit was primarily driven by a significant reduction in ischemic complications, specifically myocardial infarction (MI) and urgent target vessel revascularization (TVR).
- Importantly, the personalized approach did not lead to a statistically significant increase in major bleeding events (BARC type 2, 3, or 5) compared to the standard 12-month therapy.
- These results challenge the conventional 12-month ‘one-size-fits-all’ DAPT standard, suggesting that a precision-medicine approach to antithrombotic duration optimizes the balance between ischemic and hemorrhagic risks.
